Hyperopia, Myopia, Refractive Ametropia
Conditions
Brief summary
The purpose of this study is to assess long term performance and safety of AONDA in a real world setting when worn as daily wear or continuous wear for vision correction. This study will be used to support AONDA's marketability in Europe and other locations.
Detailed description
In this retrospective observational study, the subject used AONDA for at least approximately 1 year in either a daily wear (DW) or continuous wear (CW) modality with monthly replacement. For the CW cohort only, 3-year data will be collected, if available.
Interventions
DEVICELotrafilcon A spherical contact lenses
CE-marked silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia) in persons with minimal astigmatism that does not interfere with visual acuity
Sponsors
Alcon Research
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
Key Inclusion Criteria: * Normal eyes, as determined or known by the investigator; * Manifest refraction cylinder less than or equal to 0.75 diopter (D) in each eye at baseline; * Best Corrected Visual Acuity (BCVA) of 20/25 Snellen or better in each eye at baseline; * At the time of the 1-year visit, subject was prescribed and wearing AONDA in both eyes in either a DW or CW modality for at least approximately 1 without changing modality; * Baseline and 1-year visit chart available; * Other protocol-specified inclusion criteria may apply. Key
Exclusion criteria
* Any recurrent history or active anterior segment infection, inflammation, abnormality, or disease contraindicating regular contact lens wear present at baseline; * The use of systemic or ocular medications contraindicating regular contact lens wear at baseline; * History of refractive surgery or irregular cornea; * Slit lamp findings, including signs of pathological dry eye, that would contraindicate regular contact lens wear at baseline; * Other protocol-specified
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Distance visual acuity at Year 1 - DW Cohort | Year 1 | The subject's chart will be reviewed for a distance visual acuity assessment at 1 year after the baseline exam. The 1-year visit will be defined as a visit which occurred 1 year (-2/+4 months) since baseline, during which period the subject was wearing AONDA, and a contact lens examination was performed. Baseline will be defined as the first office visit where the investigator provided an in-person office biomicroscopy exam to the patient, before or during which a contact lens prescription for AONDA was released. |
| Distance Visual Acuity at Year 1 - CW Cohort | Year 1 | The subject's chart will be reviewed for a distance visual acuity assessment at 1 year after the baseline exam. The 1-year visit will be defined as a visit which occurred 1 year (-2/+4 months) since baseline, during which period the subject was wearing AONDA, and a contact lens examination was performed. Baseline will be defined as the first office visit where the investigator provided an in-person office biomicroscopy exam to the patient, before or during which a contact lens prescription for AONDA was released. |
| Distance Visual Acuity at Year 3 - CW Cohort | Year 3 | The subject's chart will be reviewed for a distance visual acuity assessment at 3 years after the baseline exam. The 3-year visit will be defined as a visit which occurred 3 years (-2/+8 months) since baseline, during which period the subject was wearing AONDA and a contact lens examination was performed. The 3-year visit will be applicable only if the chart indicates the subject was wearing AONDA since baseline and 1-year. |
| Incidence of Corneal Infiltrative Events up to Year 1 - DW Cohort | Up to Year 1 | The subject's chart will be reviewed for corneal infiltrative adverse events occurring after the baseline exam. Baseline will be defined as the first office visit where the investigator provided an in-person office biomicroscopy exam to the patient, before or during which a contact lens prescription for AONDA was released. |
| Incidence of Corneal Infiltrative Events up to Year 1 - CW Cohort | Up to Year 1 | The subject's chart will be reviewed for corneal infiltrative adverse events occurring after the baseline exam. Baseline will be defined as the first office visit where the investigator provided an in-person office biomicroscopy exam to the patient, before or during which a contact lens prescription for AONDA was released. |
| Incidence of Corneal Infiltrative Events Up to Year 3 - CW Cohort | Up to Year 3 | The subject's chart will be reviewed for corneal infiltrative adverse events occurring after the baseline exam. Baseline will be defined as the first office visit where the investigator provided an in-person office biomicroscopy exam to the patient, before or during which a contact lens prescription for AONDA was released. |
| Incidence of Microbial Keratitis up to Year 1 - DW Cohort | Up to Year 1 | The subject's chart will be reviewed for incidences of microbial keratitis occurring after the baseline exam. Baseline will be defined as the first office visit where the investigator provided an in-person office biomicroscopy exam to the patient, before or during which a contact lens prescription for AONDA was released. |
| Incidence of Microbial Keratitis up to Year 1 - CW Cohort | Up to Year 1 | The subject's chart will be reviewed for incidences of microbial keratitis occurring after the baseline exam. Baseline will be defined as the first office visit where the investigator provided an in-person office biomicroscopy exam to the patient, before or during which a contact lens prescription for AONDA was released. |
| Incidence of Microbial Keratitis up to Year 3 - CW Cohort | Up to Year 3 | The subject's chart will be reviewed for incidences of microbial keratitis occurring after the baseline exam. Baseline will be defined as the first office visit where the investigator provided an in-person office biomicroscopy exam to the patient, before or during which a contact lens prescription for AONDA was released. |
Countries
United States
Outcome results
None listed